Fig. 5. Sorafenib fails to trigger ferroptosis among various cell lines with high xCT expression.

a Immunoblots of xCT in WT HT1080, SLC7A11^KO HT1080, A375 melanoma, A549 lung cancer, HLE hepatoma, HT29 colon cancer, MDA-MB-436 breast cancer, U-373 glioma, and UMRC2 kidney cancer cells. VCP was used as a loading control. b Cell viability of A375, A549, HT29, MDA-MB-436, U-373, and UMRC2 cells treated with indicated concentrations of sorafenib, sulfasalazine, or erastin, in the absence or presence of 50 μM β-ME, 1 μM Lip-1, or 100 μM DFP for 24 h. Data are presented as mean ± s.d. of n = 3 wells of a 96-well plate from one representative of three independent experiments.